Development of tumor-targeted-combination therapies on PEGylated gold nanoparticle platform

Giulio is the primary inventor of Cytimmune’s technologies. He left the company at the end of 2015, but returned in 2020 to lead Cytimmune’s R&D and manufacturing efforts. Giulio has won multiple National Institute of Standards and Technology (NIST) and Small Business Innovation Research grants for his work. He has also led product development for at least three therapeutics that have entered, or are preparing to enter clinical trials.